Acadia Pharmaceuticals, a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, has
appointed John J. Kaiser as VP/strategic marketing and commercial development.
Kaiser joins Acadia from Eli Lilly & Co., where he held a variety of marketing and commercial management
positions over a more than 25-year career.
At Eli Lily, he was responsible for establishing the business and brand strategy for Cymbalta, developing global market research in support of the
successful launch of Zyprexa, and managing the global Prozac brand and associated marketing activities.
--Nina M. Lentini